Mesenchymal stem cell therapy - SCM Lifescience/University of Utah
Alternative Names: Cell sheet therapyLatest Information Update: 25 Nov 2021
At a glance
- Originator SCM Lifescience; University of Utah
- Developer SCM Lifescience
- Class Antifibrotics; Cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Renal fibrosis
Most Recent Events
- 25 Nov 2021 Preclinical trials in Renal fibrosis in South Korea (Parenteral) (SCM Lifescience pipeline, November 2021)
- 25 Nov 2021 Preclinical trials in Renal fibrosis in USA (Parenteral) (SCM Lifescience pipeline, November 2021)
- 07 Apr 2020 Early research in Renal fibrosis in South Korea (Parenteral)